Paraparetic variant of Guillain-Barré syndrome

The paraparetic variant of Guillain-Barré syndrome (GBS) is a rare, localized form of acute inflammatory polyneuropathy that predominantly affects the lower limbs. Unlike classic GBS, which typically presents with ascending weakness involving all four limbs, this variant is characterized by weakness that is largely or exclusively confined to the legs, mimicking a paraparesis or paraplegia. It is also sometimes referred to as 'paraparetic GBS' or the 'leg predominant' variant of Guillain-Barré syndrome. The condition affects the peripheral nervous system, specifically the motor and sometimes sensory nerves supplying the lower extremities. Patients typically present with acute or subacute onset of bilateral leg weakness, reduced or absent deep tendon reflexes in the lower limbs, and variable sensory symptoms such as numbness or tingling in the legs and feet. Some patients may also experience lower back or leg pain. Upper limb strength is relatively preserved, which can make initial diagnosis challenging, as the presentation may be confused with spinal cord pathology (myelopathy) or cauda equina syndrome. Nerve conduction studies typically reveal features consistent with either demyelinating or axonal neuropathy, and cerebrospinal fluid analysis may show albuminocytologic dissociation (elevated protein with normal cell count), similar to classic GBS. The condition is often preceded by a respiratory or gastrointestinal infection. Treatment follows the same principles as classic GBS and includes intravenous immunoglobulin (IVIg) or plasma exchange (plasmapheresis), which are the standard first-line therapies. Supportive care, including physical rehabilitation, pain management, and monitoring for respiratory compromise, is also important, although respiratory failure is less common in this variant compared to classic GBS. The prognosis is generally favorable, with most patients achieving significant or complete recovery, though the timeline for recovery can vary from weeks to months. Early recognition and treatment are important to optimize outcomes.

Common questions about Paraparetic variant of Guillain-Barré syndrome